Learn Before
Concept
Methods of CoVLP Phase 1 Trial
- A randomized, partially-blinded, prime-boost, 21 days apart, dose escalation phase 1 study
- one 3.75, 7.5 or 15 µg dose admininstered intramuscularly alone or with CpG1018 or AS03
- Participants were SARS-CoV-2 seronegative adults between the ages of 18-55 years
- Primary endpoints of safety and immunogenicity were reported until 42 days after vaccine administration
- The presence of neutralizing antibodies was determined using a "VSV pseudovirus assay and cellular responses by ELISpot (IFNγ, IL-4)"
0
1
Updated 2020-11-23
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences